Close Menu

NEW YORK – Veracyte said after the market closed Tuesday afternoon that it has priced a public offering of 6 million shares of its common stock at $30 per share. It expects gross proceeds of around $180 million.

Veracyte will use the net proceeds from the offering for working capital and other general corporate purposes. The firm may also use part of the proceeds to acquire or invest in complementary businesses, technologies, or other assets.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.